Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes
Our study indicates rapidly shifting trends in tirzepatide uptake among patients with CKD both with and without diabetes. The uptake of tirzepatide is expected to increase further. Future studies on the comparative effectiveness and safety of tirzepatide in patients with CKD are warranted.
Authors
- Panupong Hansrivijit (ORCID: https://orcid.org/0000-0002-5041-4290)
- Elisabetta Patorno (ORCID: https://orcid.org/0000-0002-8809-9898)
- Janinne Ortega-Montiel (ORCID: https://orcid.org/0000-0001-8196-6648)
- Deborah J. Wexler (ORCID: https://orcid.org/0000-0001-6979-402X)
- Julie M. Paik (ORCID: https://orcid.org/0000-0002-1315-5445)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- VA Boston Healthcare System (US)
- Massachusetts General Hospital (US)
- Geriatric Research Education and Clinical Center (US)
Publication Details
- Journal
- Kidney Medicine
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1016/j.xkme.2025.101013
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88
Funders
- Boehringer Ingelheim
- National Institutes of Health
- U.S. Food and Drug Administration
- National Institute of Diabetes and Digestive and Kidney Diseases